Woodbridge, CT (PRWEB) October 2, 2010
ChemWerth, Inc., has appointed Dr. Jeffrey Bauer as President effective today. Dr. Bauer takes on the responsibility for leading the day-to-day business operations of ChemWerth, as well as charting its future growth strategy. “Jeff Bauer is an outstanding talent who is widely recognized throughout the generic pharmaceutical industry as a results-driven thought-leader and visionary. I am highly confident that Jeff will take our business to the next level,” said ChemWerth founder and CEO Peter Werth.
“I am extremely excited by the opportunity to lead ChemWerth, a company which pioneered API sourcing in China,” said Dr. Bauer. “Given ChemWerth’s strong brand and its experienced staff, I intend to expand our reach in bringing unique and creative pharmaceutical business solutions to our customers worldwide.”
Prior to joining ChemWerth, Dr. Bauer held the position of Vice President, Business Development and Licensing at Sandoz, Inc. (Princeton, NJ), a position that he held for five years beginning in 2005. At Sandoz, Dr. Bauer had broad responsibilities including management of the United States generic product portfolio as well as active pharmaceutical ingredient (API) sourcing and procurement. Prior to joining Sandoz, Dr. Bauer was employed at Eon Labs, Inc., another generic pharmaceutical company that was acquired by Sandoz in July 2005. During his five year tenure at Eon Labs, he served as Vice President of Business Development and Licensing with similar responsibilities and duties as those he held at Sandoz. Dr. Bauer’s previous experience included positions at Ivax Pharmaceuticals, AAIPharma and Bio-Rad Laboratories in which he served in various capacities including: regulatory affairs, project management, portfolio management and API sourcing. In all, he brings 18 years of professional experience in the pharmaceutical and medical device industries. Dr. Bauer earned a Bachelor of Science in Biology from Tufts University in Boston, a Master of Science in Toxicology from Duquesne University and his Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill.
ChemWerth is a full service Generic Active Pharmaceutical Ingredient development and supply company specializing in oral, injectable, topical and veterinary products at competitive prices. Founded in 1982 to supply the emerging generic pharmaceutical industry with sources of reliable, high quality APIs, ChemWerth represents numerous FDA approved facilities in China, as well as a growing number of cGMP manufacturing facilities in the United States, Europe and India. For more information about the company please visit http://www.chemwerth.com.
# # #